Efficacy of Pilocarpine and Bromhexine in Improving Radiotherapy-induced Xerostomia

Farid Abbasi1 • Sareh Farhadi2* • Mostafa Esmaili3

1 Associate Professor, Department of Oral Medicine, Faculty of Dentistry, Shahed University, Tehran, Iran
2 Assistant Professor, Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Shahed University, Tehran, Iran
3 Assistant Professor, Department of Oral Medicine, Faculty of Dentistry, Shahed University, Tehran, Iran
*Corresponding Author; E-mail: dr.sfarhadi@gmail.com

Received: 17 January 2012; Accepted: 6 March 2013
J Dent Res Dent Clin Dent Prospect 2013;7(2):86-90 | doi: 10.5681/joddd.2013.015
This article is available from: http://dentistry.tbzmed.ac.ir/joddd

© 2013 The Authors; Tabriz University of Medical Sciences
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and aims. Xerostomia is one of the most common complications of head and neck radiotherapy. The aim of this study was to evaluate and compare the efficacy of pilocarpine and bromhexine in improving radiotherapy-induced xerostomia and its associated symptoms.

Materials and methods. In this single-blind, randomized crossover study, pilocarpine and bromhexine tablets were used by twenty-five patients suffered from xerostomia, with a medical history of head and neck radiotherapy. At step A, the patients were treated with pilocarpine for 2 weeks. In addition, they were asked to take bromhexine for 2 weeks with a one-week washout period. At step B, the inverse process was conducted (first bromhexine, then pilocarpine). Whole resting saliva was collected from patients before and after receiving each medication by precise measurements. Then, efficacy of the two drugs in the treatment of xerostomia and its related oral complications was evaluated using questionnaires by Dichotomous format. The results were statistically analyzed using t-student and Fisher’s exact and chi-squared tests. Statistical significance was set at P<0.05.

Results. The difference between saliva secretion rates before and after medications was not significant for bromhexine users at two steps of the study (P=0.35); however, it was significant for pilocarpine users (P=0.0001). Users of both drugs showed significant differences in improvement of xerostomia, chewing, swallowing, tasting and mouth burning.

Conclusion. Pilocarpine is probably more effective in improving xerostomia and its associated problems compared with bromhexine, although the use of the latter was also shown to ease some of the consequences of radiotherapy in the head and neck region.

Key words: Bromhexine, pilocarpine, radiotherapy, xerostomia.
Introduction

The importance of saliva in protecting the oral cavity becomes more apparent when malfunction of salivary glands results in xerostomia. The problems experienced by patients may include a persistent dry or burning sensation, eating difficulties, diminution in taste acuity, discomfort during speaking, mucosal infections, denture intolerance and bacterial sialadenitis. These symptoms reflect not only the mechanical function (moisture, irrigation and lubrication) of saliva, but also its buffering properties.

Nowadays, consumption of antidepressant drugs, radiotherapy of the head and neck region and some systemic diseases, such as diabetes mellitus, are some of the conditions that induce xerostomia. Radiotherapy is used for suppression of malignant cells but injury to normal cells can be inevitable. Most of the patients with a history of head and neck radiotherapy complain of some degrees of xerostomia due to presence of salivary glands in the radiation field. Hence, destruction of gnathic bone and oral mucosa might be notable. A reduction in salivary flow rate and decrease of its pH is paralleled with a change in saliva competence and shifting of oral microflora to cariogenic bacterial spices. Therefore, discomfort in chewing, swallowing, speech, sleep and also progressing of periodontal diseases and dental caries probably occur in the presence of xerostomia.

Studies have led to four therapeutic suggestions for xerostomia: preventive and symptomatic treatments, local and systemic stimulation. In relation to systemic medications, bromhexine is recognized as a diluting agent of mucous secretions in respiratory tract and pilocarpine is a parasympathomimetic medication acting as salivary and lacrimal secretion stimulator. Many studies have verified that pilocarpine can provide clinically significant symptomatic relief to patients suffering from radiotherapy-induced xerostomia and also in cases of Sjögren syndrome, but there are few studies about efficacy of bromhexine in these cases. Furthermore, we could not find any reports making comparisons between efficacy of pilocarpine and bromhexine in these conditions.

Therefore, this study was designed to evaluate and compare the efficacy of pilocarpine and bromhexine in improving radiotherapy-induced xerostomia and its associated symptoms.

Materials and Methods

This single-blind, randomized crossover study evaluated twenty-five patients of Imam Reza Hospital of Kermanshah, Iran, who suffered from xerostomia and their medical history showed head and neck radiotherapy, corresponding to similar studies in this manner. All the patients were over 18 years of age and had been treated with more than 4500cGy of radiation dose in 6.5 weeks more than 6 months previously. Patients with recurrent cancer, diabetes mellitus, asthma, consumption of antidepressant drugs and sensitivity to pilocarpine and bromhexine were excluded from the study. After taking an informed consent, the study was planned in 2 steps of A and B in order to reduce experimental errors. At step A, the patients were advised to use 5-mg pilocarpine tablets (Mahya Daroo Co.) 4 times daily for 2 weeks. After 2 weeks, the patients were asked to stop taking the drug for one week in order to obliterate the pharmacologic effects of the drug (wash-out period). Then, they were asked to take 8-mg bromhexine tablets (Mucolin tablets, Tolidaroo Co.) 4 times daily for 2 weeks. The inverse process was conducted at step B (first bromhexine, then pilocarpine). The patients’ whole resting saliva was collected and measured precisely before and after every course of medication by two experts: one oral medicine specialist and one student of dentistry who was trained in this procedure. The resting saliva secretion was measured using spitting methods and levels of lower than 0.01 mL reflected dysfunction of salivary glands. The patients were not informed about the prescribed drugs as dictated by the single-blind research design.

Then, the patients answered the self-administered questionnaire, during the first visit (zero day) and fourteen days after taking the medication; this was repeated for another drug in the same manner. The questionnaire was designed by a specialist of oral medicine in relation to dichotomous scale, including 15 questions about xerostomia and its oral complications such as swallowing, speech, tasting problems and burning sensation.

Improvement of xerostomia and other oral complications was statistically analyzed by chi-squared and Fisher’s exact tests. Increase in saliva secretion, before and after medication, was analyzed by Student’s t-test. Statistical significance was defined at P<0.05.

Results

Tables 1 and 2 show the rate of saliva secretion at step A (first pilocarpine, then bromhexine) and B (first bromhexine, then pilocarpine), respectively, in four separate evaluations: before and after first
evaluation and before and after second evaluation. Comparisons between the rate of secretion showed no significant differences in bromhexine users (P=0.35) but there were significant differences in pilocarpine users (P=0.0001).

Furthermore, 28% and 100% of bromhexine and pilocarpine users showed improvement of xerostomia after fourteen days, respectively. Statistical analysis showed significant differences in improvement of xerostomia for users of both medications (P=0.0001).

All the (100%) pilocarpine users and 14.3% of bromhexine users demonstrated improvement of chewing difficulties; similarly, 87.5% of pilocarpine users and 25% of bromhexine users showed improvements in swallowing problems; 100% of pilocarpine users and 14.3% of bromhexine users, reported relief of speech problems and 90.9% of pilocarpine users and 20.8% bromhexine users showed improvements in tasting difficulties. Finally, 100% of pilocarpine users and 66.7% of bromhexine users demonstrated improvements in burning sensation. All the differences mentioned were statistically significant with P-values of 0.0001, 0.04, 0.005, 0.0001 and 0.004 for improvement in chewing, swallowing, speech, tasting problems and burning sensation, respectively.

**Discussion**

Radiotherapy of head and neck may result in a decrease in salivary pH and its rate of secretion. Therefore, any discomfort of chewing, swallowing, speech and sleep may occur in the presence of xerostomia. In order to relieve these oral discomforts, salivary stimulating drugs, such as pilocarpine and bromhexine, have been used for some years and their efficacy has been verified in some experimental studies.

In the present study, improvement of xerostomia was shown using both medications. Chitapanarux et al.\textsuperscript{17} and Ram et al.\textsuperscript{20} in line with this study, reported that pilocarpine has obvious palliative effects on xerostomia and sleep of patients. Previous studies\textsuperscript{21-23} have shown that pilocarpine has a great ability to prevent radiotherapy-induced xerostomia. Haddad et al.\textsuperscript{24} showed the preventive effect of both drugs and Wu et al.\textsuperscript{25} reported that pilocarpine can improve xerostomia induced by Sjögren syndrome. Although, some researchers have reported that pilocarpine increases saliva secretion,\textsuperscript{26,27} Warde et al, contrary to the results of the present study, reported no significant differences in recovery from xerostomia and quality of life between pilocarpine and placebo users.\textsuperscript{28} It seems that use of VAS scale in their study and different frequencies of drug administration can explain this lack of difference.

Notable effects of pilocarpine have been confirmed in improving radiotherapy-induced xerostomia,\textsuperscript{10-12,24} Sjögren syndrome\textsuperscript{29} and immune dysfunction conditions.\textsuperscript{30} Given the efficacy of this medication in increasing saliva secretion, the practitioners have preferred to advise it rather than artificial saliva in these situations; however, indication of pilocarpine prescription was limited in cases with complete suppression of salivary gland function. On the other hand, there are few scientific reports on bromhexine with definite results. However, Avisar et al.\textsuperscript{32} and Frost-larsen et al.\textsuperscript{33} showed improvement of xerostomia with administration of bromhexine in cases of Sjögren syndrome.

The present study showed significant differences in all the signs and symptoms of radiotherapy-induced xerostomia using both medications, though pilocarpine showed a more effective role compared with bromhexine. Previous studies\textsuperscript{34-36} have shown significant increases in saliva secretion following pilocarpine administration. Frost-larsen et al.\textsuperscript{33} in line with the present study, reported significant increases in saliva secretion after bromhexine administration but Misawa et al.\textsuperscript{17} could not find any significant differences. Different etiologies of xerostomia in these studies can probably explain the situation.

The present single-blind study generally showed the superiority of Pilocarpine to Bromhexine in improving radiotherapy-induced xerostomia but further investigations are necessary to compare the long-term efficacy of these two drugs. In addition, application of quality of life questionnaire in 100-scale VAS might be a more precise evaluation of the situation.
Conclusion

Pilocarpine is probably more effective in improving xerostomia and its associated problems compared with bromhexine, although the use of the latter was also shown to remove some consequences of radiotherapy in the head and neck region.

References

1. Mandel ID. The functions of saliva. J Dent Res 1987;66:623-7.
2. Chambers MS, Toth BB, Martin JW, Fleming TJ, Lemon JC. Oral and dental management of the cancer patient: prevention and treatment of complications. Support Care Cancer 1995;3:168-75.
3. Ferguson PM. Pilocarpine and other cholinergic drugs in the management of salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1993;75:186-91.
4. Burket LW, Greenberg M, Click M. Burket's oral medicine 11th ed. BC Decker Inc; 2008: P. 214-5.
5. Greenberg MS. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;97:28-46.
6. Regelink G, Vissink A, Reintsema H, Nauta JM. Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quint Int 1998; 29:383-8.
7. Jay SC. Moss Radiation Oncology 7th Ed. The CV Mosby Co;1994:205.
8. Valdes Olmos RA, Kevs RB. Scintigraphic assessment of salivary function and excretion response in radiation induced injury of the major salivary glands. Cancer 1994;73:2886-93.
9. Brown LR, Dreizen S, Handler S, Johnston DA. Effect of radiation-induced xerostomia on human oral microflora. J Dent Res 1975;54:740-50.
10. LeVeque FG, Montgomery M, Potter D, Zimmer MB, Rieke JW, Steiger BW, et al. A multicenter, randomized, double-blind, placebo-controlled, dose-titration study of oral pilocarpine for treatment of radiation-induced xerostomia in head and neck cancer patients. J Clin Oncol 1993;11:1124-31.
11. Horiot JC, Lipinski F, Schraub S, Maulard-Durdux C, Bensadoun RJ, Ardieit JM, et al. Post-radiation severe xerostomia relieved by pilocarpine: a prospective French cooperative study. Radiother Oncol 2000;55:233-9.
12. Johnson JT, Ferretti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, et al. Oral pilocarpine for postirradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993;329:390-5.
13. Davies AN. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. Palliative Medicine 2000;14:197-203.
14. Haddad P, Karimi M. A randomized, double-blind, placebo-controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation-induced xerostomia. Radiotherapy and Oncology 2002;64:29-32.
15. Sweeney MP, Bagg J, Baxter WP, Atchison Tc. Clinical trial of a mucin containing oral spray for treatment of xerostomia in hospice patients. Palliative medicine 1997;11:225-32.
16. Fox PC. Salivary enhancement therapies. Caries Res 2004;38:241-6.
17. Chitapanarux I, Kamnerdsupaphon P, Tharavichtikul E, Sumitsawan Y, Sittitirat P, Pattarasukulchai T et al. Effect of Oral Pilocarpine on Post-Irradiation Xerostomia in Head and Neck Cancer Patients. A Single-Center, Single-Blind Clinical Trial. J Med Assoc Thai 2008;91:1410-5.
18. Mätzner P, Burian A, Martin W, Annoni O, Lauro V, Tacchi R et al. A Randomised, Two-Period, Cross-Over, Open-Label Study to Evaluate the Pharmacokinetic Profiles of Single Doses of Two Different Flurbiprofen 8.75-mg Lозenges in Healthy Volunteers. Pharmacology 2012;89:1889-91.
19. Kakoei S, Haghdooost AA, Rad M, Mohammadalizadeh S, Pourdamghan N, Nakhahi M et al. Xerostomia after radiotherapy and its effect on quality of life in head and neck cancer patients. Arch Iran Med 2012;15:214-8.
20. Ram S, Kumar S, Navazesh M. Management of xerostomia and salivary gland hypofunction. J Calif Dent Assoc 2011;39:656-9.
21. Fardesfahani A, Moddarees M. Quantitative evaluation of salivary gland function with Radioisotope Tc99m scan for prevention of radiotherapy-induced xerostomia. Journal of Iran Nuclear medicine 2006;3: 11-20 [Persian].
22. Reiger JM, Gha N, Lam Tang JA. Functional outcomes related to the prevention of radiation-induced xerostomia: Oral Pilocarpine versus submandibular salivary gland transfer. Head Neck 2012; 34:168-74.
23. Berk L. Systemic pilocarpine for treatment of xerostomia. Expert Opin Drug Metab Toxicol 2008; 4:1333-40.
24. Ho C, Murray N, Laskin J. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer 2005;49:225–31.
25. Wu CH, Hsieh SC, Lee KL, Li KJ, Lu MC, Yu CL. Pilocarpine Hydrochloride for the Treatment of Xerostomia in Patients with Sjogren's Syndrome in Taiwan - A Double-blind, Placebo-controlled Trial. J Formos Med Assoc 2006;105:796-803.
26. Papas A, Charney M, Goden H. The effectiveness of oral pilocarpine-HCL tablets for the treatment of dry mouth symptoms associated with Sjgren's syndrome- a dosettitation study. Arthritis Rheum 1997;40:202.
27. Vivino FB, Al-Hashimi I, Khan Z. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjgren's syndrome: a randomized, placebocontrolled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 1999,159:174–81.
28. Warde P, O'Sullivan B, Aslanidis J, Kroll B, Lockwood G, Waldron J.A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;54:9-13.
29. Vivino FB. The treatment of Sjogren syndrome patients with Pilocarpine-tablets. Scand J Rheumatol Suppl 2001;115:1-13.
30. Fox PC, Vander Ven PF, Baum BJ. Pilocarpine for treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1986;619:243-8.
31. Soto-Rojas AE, Kraus A: The oral side of Sjogren syndrome- a review. Arch Ophthalmol 1981;13:971-3.
32. Frost-Larsen K, Isager H, Manthorpe R, Sjogren's syndrome treated with bromhexine: a randomised clinical study. Br Med J 1978;1579-81.
34. Scarantino C, LeVeque F, Swann RS, White R, Schulsinger A, Hodson DI et al. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients. *J Support Oncol* 2006;4:252-8.

35. Bernardi R, Pein C, Becker FL, Ramos GZ, Gheno GZ, Lopez LR et al. Effect of Pilocarpine mouthwash on salivary flow. *Brazilian Journal of Medical and Biological Research* 2002;35:105-10.

36. Taweechaisupapong S, Pesee M, Aromdee C, Laopaiboon M, Khunkitti W. Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. *Aust Dent J* 2006;51:333-7.

37. Misawa M, Ohmori SH, Yanaura S. Effects of Bromhexidine on the secretions of saliva and tears. *The Japanese Journal of Pharmacology* 1985;39:241-50.